LFMDP and LFMD Related Headlines
Go Back- LifeMD names Umesh Sripad as chief technology officer
- LifeMD Appoints Umesh Sripad as Chief Technology Officer
- LifeMD to Participate in Upcoming Investor Conferences
- LifeMD Reports First Quarter 2026 Results
- LifeMD to Report First Quarter 2026 Financial Results on May 6
- LifeMD adds Eli Lilly's oral weight loss drug Foundayo to platform
- LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
- LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- LifeMD names Atul Kavthekar as chief financial officer
- LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
- LifeMD Reports Fourth Quarter and Full Year 2025 Results
- LifeMD to Participate in Two Investor Conferences During March
- LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
- LifeMD secures $50 million credit facility with Citizens Bank
- LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
- LifeMD adds Novo Nordisk's oral Wegovy pill to telehealth platform
- LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026
- LifeMD Reports Third Quarter 2025 Results
- LifeMD reduces cash prices for Wegovy and Ozempic to $199 monthly
- LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
- LifeMD to Participate in the BTIG Digital Health Forum
- LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
- LifeMD sells majority stake in WorkSimpli for $65 million valuation
- LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
- LifeMD to Report Third Quarter 2025 Financial Results on November 6
- LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women’s Health Program
- LifeMD offers Ozempic at $499 monthly via Novo Nordisk partnership
- LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
- LifeMD to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- LifeMD Expands Pharmacy Services with Non-Sterile Compounding to Deliver Personalized, Cost-Efficient Therapies at Scale
- LifeMD to Participate in Three Investor Conferences During September
- LifeMD Reports Second Quarter 2025 Results
- LifeMD to Participate in the Canaccord Genuity 45th Annual Growth Conference
- LifeMD names Shayna Webb Dray as COO, promotes two other executives
- LifeMD Names COO and Promotes Two Executives
- LifeMD to Report Second Quarter 2025 Financial Results on August 5
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LFMDP and LFMD Related Press Releases
Go Back- LifeMD Appoints Umesh Sripad as Chief Technology Officer
- LifeMD to Participate in Upcoming Investor Conferences
- LifeMD Reports First Quarter 2026 Results
- LifeMD to Report First Quarter 2026 Financial Results on May 6
- LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
- LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
- LifeMD Reports Fourth Quarter and Full Year 2025 Results
- LifeMD to Participate in Two Investor Conferences During March
- LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
- LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
- LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026
- LifeMD Reports Third Quarter 2025 Results
- LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
- LifeMD to Participate in the BTIG Digital Health Forum
- LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
- LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
- LifeMD to Report Third Quarter 2025 Financial Results on November 6
- LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women’s Health Program
- LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
- LifeMD to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
- LifeMD Expands Pharmacy Services with Non-Sterile Compounding to Deliver Personalized, Cost-Efficient Therapies at Scale
- LifeMD to Participate in Three Investor Conferences During September
- LifeMD Reports Second Quarter 2025 Results
- LifeMD to Participate in the Canaccord Genuity 45th Annual Growth Conference
- LifeMD Names COO and Promotes Two Executives
- LifeMD to Report Second Quarter 2025 Financial Results on August 5
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
